# Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer

> **NCT00003343** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 525 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** endocrine-modulating drug therapy
- **DRUG:** mitoxantrone hydrochloride
- **DRUG:** prednisone
- **DRUG:** prinomastat

## Key facts

- **NCT ID:** NCT00003343
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03
- **Primary completion:** 2001-01
- **Final completion:** —
- **Target enrollment:** 525 (ESTIMATED)
- **Last updated:** 2012-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003343, "Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00003343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*